피브리노겐 : 시장 점유율 및 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Fibrinogen was estimated to be worth US$ 1257 million in 2024 and is forecast to a readjusted size of US$ 2525 million by 2031 with a CAGR of 10.3% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Fibrinogen cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer's products are justly used in local region or countries.

The market for fibrinogen is primarily driven by the increasing prevalence of bleeding disorders and surgical procedures that require rapid hemostasis, as well as growing awareness and adoption of targeted blood management therapies. Advances in plasma fractionation and recombinant technologies, along with rising demand for safer, pathogen-reduced, and high-purity blood products, are also fueling market growth. Additionally, an aging population, higher incidence of trauma and cardiovascular surgeries, and expansion of healthcare infrastructure in emerging regions contribute to the increasing demand for fibrinogen concentrate.

Global core fibrinogen manufacturers include CSL Behring, LFB Group and Shanghai RAAS Blood Products etc. The top 1 companies hold a share about 52%. North America is the largest market, with a share about 31%, followed by Europe and Asia Pacific with the share about 28% and 26%.

This report aims to provide a comprehensive presentation of the global market for Fibrinogen, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Fibrinogen by region & country, by Type, and by Application.

The Fibrinogen market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fibrinogen.

Market Segmentation

By Company

• CSL Behring
• LFB Group
• Shanghai RAAS Blood Products
• China Resources Boya Bio-pharmaceutical
• Hualan Biological Engineering
• Harbin Pacific Biopharmaceutical
• China Meheco Group
• Taibang Biologic
• Octapharma

Segment by Type

• Human Fibrinogen
• Animal Fibrinogen

Segment by Application

• Congenital Fibrinogen Deficiency
• Surgical Procedures
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Fibrinogen manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Fibrinogen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Fibrinogen in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Fibrinogen Product Introduction
• 1.2 Global Fibrinogen Market Size Forecast
  • 1.2.1 Global Fibrinogen Sales Value (2020-2031)
  • 1.2.2 Global Fibrinogen Sales Volume (2020-2031)
  • 1.2.3 Global Fibrinogen Sales Price (2020-2031)
• 1.3 Fibrinogen Market Trends & Drivers
  • 1.3.1 Fibrinogen Industry Trends
  • 1.3.2 Fibrinogen Market Drivers & Opportunity
  • 1.3.3 Fibrinogen Market Challenges
  • 1.3.4 Fibrinogen Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Fibrinogen Players Revenue Ranking (2024)
• 2.2 Global Fibrinogen Revenue by Company (2020-2025)
• 2.3 Global Fibrinogen Players Sales Volume Ranking (2024)
• 2.4 Global Fibrinogen Sales Volume by Company Players (2020-2025)
• 2.5 Global Fibrinogen Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Fibrinogen Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Fibrinogen Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Fibrinogen
• 2.9 Fibrinogen Market Competitive Analysis
  • 2.9.1 Fibrinogen Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Fibrinogen Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibrinogen as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Human Fibrinogen
  • 3.1.2 Animal Fibrinogen
• 3.2 Global Fibrinogen Sales Value by Type
  • 3.2.1 Global Fibrinogen Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Fibrinogen Sales Value, by Type (2020-2031)
  • 3.2.3 Global Fibrinogen Sales Value, by Type (%) (2020-2031)
• 3.3 Global Fibrinogen Sales Volume by Type
  • 3.3.1 Global Fibrinogen Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Fibrinogen Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Fibrinogen Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Fibrinogen Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Congenital Fibrinogen Deficiency
  • 4.1.2 Surgical Procedures
  • 4.1.3 Others
• 4.2 Global Fibrinogen Sales Value by Application
  • 4.2.1 Global Fibrinogen Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Fibrinogen Sales Value, by Application (2020-2031)
  • 4.2.3 Global Fibrinogen Sales Value, by Application (%) (2020-2031)
• 4.3 Global Fibrinogen Sales Volume by Application
  • 4.3.1 Global Fibrinogen Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Fibrinogen Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Fibrinogen Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Fibrinogen Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Fibrinogen Sales Value by Region
  • 5.1.1 Global Fibrinogen Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Fibrinogen Sales Value by Region (2020-2025)
  • 5.1.3 Global Fibrinogen Sales Value by Region (2026-2031)
  • 5.1.4 Global Fibrinogen Sales Value by Region (%), (2020-2031)
• 5.2 Global Fibrinogen Sales Volume by Region
  • 5.2.1 Global Fibrinogen Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Fibrinogen Sales Volume by Region (2020-2025)
  • 5.2.3 Global Fibrinogen Sales Volume by Region (2026-2031)
  • 5.2.4 Global Fibrinogen Sales Volume by Region (%), (2020-2031)
• 5.3 Global Fibrinogen Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Fibrinogen Sales Value, 2020-2031
  • 5.4.2 North America Fibrinogen Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Fibrinogen Sales Value, 2020-2031
  • 5.5.2 Europe Fibrinogen Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Fibrinogen Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Fibrinogen Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Fibrinogen Sales Value, 2020-2031
  • 5.7.2 South America Fibrinogen Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Fibrinogen Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Fibrinogen Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Fibrinogen Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Fibrinogen Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Fibrinogen Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Fibrinogen Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Fibrinogen Sales Value, 2020-2031
  • 6.3.2 United States Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Fibrinogen Sales Value, 2020-2031
  • 6.4.2 Europe Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Fibrinogen Sales Value, 2020-2031
  • 6.5.2 China Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Fibrinogen Sales Value, 2020-2031
  • 6.6.2 Japan Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Fibrinogen Sales Value, 2020-2031
  • 6.7.2 South Korea Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Fibrinogen Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Fibrinogen Sales Value, 2020-2031
  • 6.9.2 India Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Fibrinogen Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 CSL Behring
  • 7.1.1 CSL Behring Company Information
  • 7.1.2 CSL Behring Introduction and Business Overview
  • 7.1.3 CSL Behring Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 CSL Behring Fibrinogen Product Offerings
  • 7.1.5 CSL Behring Recent Development
• 7.2 LFB Group
  • 7.2.1 LFB Group Company Information
  • 7.2.2 LFB Group Introduction and Business Overview
  • 7.2.3 LFB Group Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 LFB Group Fibrinogen Product Offerings
  • 7.2.5 LFB Group Recent Development
• 7.3 Shanghai RAAS Blood Products
  • 7.3.1 Shanghai RAAS Blood Products Company Information
  • 7.3.2 Shanghai RAAS Blood Products Introduction and Business Overview
  • 7.3.3 Shanghai RAAS Blood Products Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Shanghai RAAS Blood Products Fibrinogen Product Offerings
  • 7.3.5 Shanghai RAAS Blood Products Recent Development
• 7.4 China Resources Boya Bio-pharmaceutical
  • 7.4.1 China Resources Boya Bio-pharmaceutical Company Information
  • 7.4.2 China Resources Boya Bio-pharmaceutical Introduction and Business Overview
  • 7.4.3 China Resources Boya Bio-pharmaceutical Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 China Resources Boya Bio-pharmaceutical Fibrinogen Product Offerings
  • 7.4.5 China Resources Boya Bio-pharmaceutical Recent Development
• 7.5 Hualan Biological Engineering
  • 7.5.1 Hualan Biological Engineering Company Information
  • 7.5.2 Hualan Biological Engineering Introduction and Business Overview
  • 7.5.3 Hualan Biological Engineering Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Hualan Biological Engineering Fibrinogen Product Offerings
  • 7.5.5 Hualan Biological Engineering Recent Development
• 7.6 Harbin Pacific Biopharmaceutical
  • 7.6.1 Harbin Pacific Biopharmaceutical Company Information
  • 7.6.2 Harbin Pacific Biopharmaceutical Introduction and Business Overview
  • 7.6.3 Harbin Pacific Biopharmaceutical Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Harbin Pacific Biopharmaceutical Fibrinogen Product Offerings
  • 7.6.5 Harbin Pacific Biopharmaceutical Recent Development
• 7.7 China Meheco Group
  • 7.7.1 China Meheco Group Company Information
  • 7.7.2 China Meheco Group Introduction and Business Overview
  • 7.7.3 China Meheco Group Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 China Meheco Group Fibrinogen Product Offerings
  • 7.7.5 China Meheco Group Recent Development
• 7.8 Taibang Biologic
  • 7.8.1 Taibang Biologic Company Information
  • 7.8.2 Taibang Biologic Introduction and Business Overview
  • 7.8.3 Taibang Biologic Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Taibang Biologic Fibrinogen Product Offerings
  • 7.8.5 Taibang Biologic Recent Development
• 7.9 Octapharma
  • 7.9.1 Octapharma Company Information
  • 7.9.2 Octapharma Introduction and Business Overview
  • 7.9.3 Octapharma Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Octapharma Fibrinogen Product Offerings
  • 7.9.5 Octapharma Recent Development

8 Industry Chain Analysis

• 8.1 Fibrinogen Industrial Chain
• 8.2 Fibrinogen Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Fibrinogen Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Fibrinogen Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer